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Basal levels of monoamines and DHEA in four main limbic brain regions were measured in prepubertal Wistar Kyoto (WKY)
rats (a putative animal model of childhood depression). Basal levels of “Brain-Derived Neurotrophic Factor (BDNF)” were also
determined in two regions in the hippocampus, compared with Wistar strain controls. In the second phase, we examined the
responsiveness of prepubertal WKY rats to diﬀerent types of chronic antidepressant treatments: Fluoxetine, Desipramine, and
dehydroepiandrosterone sulfate (DHEAS). WKY prepubertal rats exhibited diﬀerent monoamine levels in the limbic system,
reduced DHEA levels in the VTA and lower levels of BDNF in the hippocampus CA3 region compared to controls. In prepubertal
WKYrats,onlytreatmentwithDHEASproducedastatisticallysigniﬁcantdecreaseinimmobility,comparedtosaline-administered
controls in the forced swim test. Wistar controls were not aﬀected by any antidepressant. The results imply that DHEA(S) and
BDNF may be involved in the pathophysiology and pharmacotherapy of childhood depression.
Copyright © 2009 O. Malkesman et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Introduction
Major depression in children and adolescents is common,
recurrent, and associated with signiﬁcant morbidity and
mortality [1]. The point prevalence of depressive disorders is
1%–2% of prepubertal children and 3%–8% of adolescents,
with a lifetime prevalence of approximately 20% by the end
of adolescence (for review see [2]).
Despite similarities in the clinical picture and longitudi-
nal course of major depression in children, adolescents, and
adults [3], there are notable diﬀerences in the neurobiologi-
cal correlates and treatment response of depressed patients
in these diﬀerent age cohorts [4]. Depressed children and
adolescents do not show evidence of hypercortisolemia as
frequently as is reported in depressed adults [5], and most
notably, depressed children fail to respond to antidepressant
treatment as well as adults do [6]. For example, most of the
trials with tricyclic antidepressants in both children [6]a n d
adolescents[6,7]havenotbeenshowntobemoreeﬃcacious
than placebo, and only 3 (20%) of 15 antidepressants trials
submitted to the FDA for pediatric depression demonstrated
superiority of drug over placebo [8]. These diﬀerences
between adult and childhood depression may indicate that
some aspects of pathophysiology in monoaminergic circuits
are unique to childhood depression [9].
Current antidepressant medications are based mostly
on brain monoamine modulation. The weak response of
depressed prepubertal children to conventional, clinically
used antidepressants in contrast to adults [6] might imply
that other non-monoaminergic factors may aﬀect childhood
depression.
In the current study, we examined candidate novel
mechanisms (with possible antidepressant potential) for
childhood depression by using a putative genetic animal2 Advances in Pharmacological Sciences
model for childhood depression: Wistar Kyoto (WKY)
rats, derived from Wistar rats [10–12]. WKY prepubertal
rats exhibited depression-like symptoms in a battery of
behavioral tests and physiological measurements in earlier
studies in our laboratory; including: anhedonic behavior
[10]; long immobility duration in the swim test [11];
hypercortisolism [11]; and in infant rats-abnormal emotion-
regulation capacities [12, 14]. Hence, the use of these young
animals for studying potential mechanisms and antidepres-
sant approaches appears to be appropriate and particularly
relevantforexploringnewtreatmentstrategiesforchildhood
depression. It is important to mention that though earlier
ﬁndings from our laboratory suggest that though prepu-
bertal FSL and WKY rats are both validated genetic animal
models of childhood depression, they are fundamentally
diﬀerent. It seems that we have two diﬀerent subgroups
of animal models for childhood depression modeling two
distinct clinical depressive syndromes (DMS-IV) that can
also be found in depressed children and adolescents [15].
In general, the data on the WKY rats would seem most
consistent with a melancholic depression proﬁle. This is
based on two characteristics: hypercortisolism—most con-
sistent neuroendocrine alteration observed in patients with
melancholic depression [16] and anhedonic-like behavior—
the core symptom of the melancholic subtype of major
depressive disorder [17]. On the other hand, data on the FSL
rats would seem most consistent with atypical depression
[18]—showing less classical symptoms of depression and
showing no comorbidity of depression and anxiety [10, 11].
In the current study, we chose to focus on the more pro-
totypical depressive proﬁle—melancholic depression. Thus,
t h eu s eo fW K Yp r e p u b e rt a lra t ss e e m st ob ea p p r o p ri a t ea n d
particularly relevant in order to explore potential relevant
brain mechanisms and to suggest potential new treatment
strategies for childhood depression.
Though it is believed that depletion of serotonin and/or
dopamine is one of the causes of depression [19], and
depression can be treated by drugs increasing this activity
[20], the monoaminergic hypothesis has not been able
to provide adequate explanations for the pathogenesis of
depression [21].
In recent years, it has been shown that Dehydroepian-
drosterone (DHEA) and its sulfate ester (DHEAS) play a
role in the neurobiology of depression (for review, see
[22]) and even possess antidepressant-like properties [23,
24] that can be explained by the interaction between the
sigma 1 receptor agonist DHEA(S) [25] and noradrenaline
and serotonin neurotransmission. A recent review suggests
that neurosteroids, including DHEA and DHEAS, may be
involved in the pathophysiology and pharmacotherapy of a
variety of disorders in children and adolescents, including
depression [26]. Accordingly, concentrations of DHEA and
DHEAS in humans typically decrease steadily with age [22]
and it has been proposed that DHEA as well as DHEAS
may play a role in neurodevelopment, due to a transient
expression of steroidogenic enzyme (P450c17) and the
potential ability of DHEA(S) to regulate neuronal pathway
formation [22, 27]. Thus, DHEA(S) may potentially play an
important role in (childhood and adult) depression, both
because of its antidepressive eﬀect and its role in neuronal
pathway formation.
The neurotrophic factor hypothesis is one of the latest
theories of the pathophysiology of depression. Neurotrophic
factors were ﬁrst characterized for regulating neural growth
and diﬀerentiation during development, but are now known
to be also potent regulators of plasticity and survival of
adult neurons and glia [28]. The “neurotrophin hypoth-
esis of depression” is based largely on observations that
decrease in hippocampal BDNF levels are correlated with
stress-induced depressive behaviors and that antidepressant
treatment enhances the expression of BDNF (see [29]f o r
review). Therefore, the BDNF hypothesis postulates that
a loss of BDNF is directly involved in the pathopysiology
of depression, and that its restoration may underline the
therapeutic eﬃcacy of antidepressant treatment [30].
Several lines of evidence suggest that BDNF might be
an important agent of therapeutic recovery from depression,
and it might also provide protection against stress-induced
neuronal damage [28, 31]. Chronic (but not acute) admin-
istration of virtually all classes of antidepressants increased
BDNF expression in the dentate gyrus and the pyramidal
cell layer of the hippocampus in rodents [32]. The ﬁndings
could also explain why antidepressant response is delayed: it
would require suﬃcient time for levels of BDNF to gradually
rise and exert their neurotrophic eﬀects [28]. Furthermore,
Shirayama et al. [33] demonstrated that a single bilateral
infusion of BDNF into the dentate gyrus of the hippocampus
producedanantidepressanteﬀectintwo(behavioral)animal
models of depression: learned helplessness and the forced
swim test. In addition, though BDNF and serotonin are
two seemingly distinct signaling systems that play regulatory
roles in many neuronal functions, a common feature of the
two systems is their ability to regulate the development and
plasticity of neuronal circuits involved in mood disorders
such as depression and anxiety. BDNF promotes the survival
anddiﬀerentiationofserotoninneurons.Conversely,admin-
istration of SSRIs enhances BDNF gene expression. There
is also evidence for synergism between the two systems in
aﬀective behaviors and genetic epistasis between BDNF and
the serotonin transporter gene (see [34] for review).
In animal models, it has been shown that stress (and
high levels of glucocorticoids) may give rise to atrophy of
the hippocampal neurons in the CA3 subregion [35]. In
addition, it has been shown that stress paradigms decrease
adult neurogenesis in the hippocampal dentate gyrus [36].
In sum, the hypothesis of BDNF and depression suggests
that if BDNF is no longer made in appropriate amounts,
instead of the neuron prospering and developing more
and more synapses, stress causes vulnerable neurons in the
hippocampus to atrophy and possibly undergo apoptosis
when their neurotrophic input is cut oﬀ. This, in turn can
lead to depression and to the consequences of repeated
depressive episodes [19].
Accordingly, due to the ﬁndings that depressed children
respond less well to antidepressant treatments, and based on
the connections between serotonin, DHEA and BDNF and
their role in neurodevelopment, we examined their levels in
an animal model of childhood depression.Advances in Pharmacological Sciences 3
In the main study, in order to identify unique brain
areas that might be implicated in children suﬀering from
depression, we measured basal levels of monoamines and
DHEA in subcortical structures of the limbic system,
which have been found to play critical roles in depression
[37]: the nucleus accumbens (NAc), the hypothalamus, the
ventral tegmental area (VTA), and the amygdala. These
areas have been found to play a critical role in domains
which are prominently aﬀected in most depressed patients
such as regulation of motivation, sleep, and responses
to pleasurable and aversive stimuli [28]. In addition, we
measured basal levels of BDNF in the CA3 and the dentate
gyrus (DG) in prepubertal WKY rats and their Wistar
controls.
In a second study, we examined how the WKY strain
respondstodiﬀerentantidepressanttreatments.Weadminis-
tered two diﬀerent clinically used antidepressants that inﬂu-
ence the brain monoaminergic system: ﬂuoxetine (a selective
serotonin reuptake inhibitor; SSRI) and desipramine (non-
selective norepinephrine reuptake inhibitor) and explored
their eﬀect on prepubertal rats from the WKY strain and
their Wistar controls. In addition, we employed DHEAS
as a potential antidepressant treatment (while being aware
that it is a steroid that could potentially inﬂuence the
pattern of sexual maturation). The eﬀectiveness of all three
diﬀerent treatments was assessed by a behavioral test often
used for screening antidepressants: a modiﬁed version of
the forced swim test of Porsolt et al. [38]. The animals
were studied at the age of 34-35 days, because at this
developmental phase, before sexual maturity, rats are able to
show immobility in the forced swim test [39]. This age also
allowed for a 2-week treatment period, starting from the day
of weaning.
2. Methods
2.1. Animals. Adult WKY and Wistar rats were bred in
our colony at Bar-Ilan University’s Speciﬁc Pathogen Free
colony at the Gonda Brain Research Center. After weaning
the pups were housed in a polypropylene cage (18.5cm
height × 26.5cm width × 43cm length), three per cage,
in a temperature controlled vivarium (20–22
◦C), under a
12h-12h light : dark cycle (lights on at 0700). Food and
water were available ad libitum. Several studies showed that
repeated short-lasting stress induced by handling alters the
action of the HPA axis [47, 48] and that mild stress of daily
injections alone may alter morphology of diﬀerent brain
regions [49]. Therefore, in the current study, osmotic mini-
pups (loaded with the antidepressant drugs or vehicle) were
implanted only in the male rats (PND 21) that were intended
to participate in the antidepressants experiment.
The animals were studied, before sexual maturity, at
the age range of 30–35 days. At this developmental phase,
rats are able to show immobility in the swim test [39],
and their developing HPA system is responsive, as the
“stress hyporesponsive period” is behind them [50]. This
developmental proﬁle is roughly similar to the prepubertal
human developmental proﬁle [51].
The study protocol was approved by the Institutional
Animal Care and Use Committee, is in accordance with
the National Institutes of Health guide for the care and use
of Laboratory animals (NIH Publications no. 8023, revised
1978) and adhered to the guidelines of the Society for
Neuroscience.
2.2. Brain Dissection and Extraction. At the age of 34-35
days, 12 male rats (4–6 of each line) were decapitated and
their brains removed rapidly, and dissected as previously
described [52]. Since DHEA is a stress-responsive hormone
[22], extra steps were made in an attempt to prevent
pre-decapitation stress: rats were waiting outside of the
decapitation room, after each animal’s decapitation gloves
were changed, and all the equipment was cleaned. Brieﬂy,
the entire hypothalamus was surgically dissected out with
forceps and frozen immediately at −80
◦C. The brains were
then placed in a rat brain mold (constructed at Bar-Ilan
University) on ice, and serial 0.5mm sections were cut and
placed on chilled microscope slides. Tissue punches (NAc,
hypothalamus, VTA, Amygdala, DG, and CA3) were taken
rapidly, using a stainlesssteel cannula with aninner diameter
of 0.6mm. The tissue samples were frozen immediately at
−80
◦C. Extraction was achieved by thawing the punches
and subjecting them to probe sonication (80W for 5s with
a B-12 Soniﬁer; Branson, Danbury, Conn, USA) in 0.3mL
of PBS on ice. A sample (10µL) was removed for protein
analysis and the rest was subjected to centrifugation (2,000g,
10min, 4◦C).The resultingsupernatants(thetissue extracts)
were divided into two separate tubes: 90µL for DHEA
determination and 60µL for monoamine determination. To
the tube containing the supernatants for the monoamine
determination we added 120µL PCA and then ﬁltered it
(0.45µm Acrodisk; Gelman, Ann Arbor, Mich, USA). Both
of the tubes were stored at −80
◦C until used for the
determination of monoamines (HPLC) or DHEA (RIA).
2.3. Analysis of Monoamine Content in the Tissue Punches.
Quantitation of the 5-hydroxytryptamine (Serotonin/5-
HT), 5-hydroxyindoeactic acid (5-HIAA), homovanillic acid
(HVA), dopamine (DA), 3,4-dihydroxy-phenylalanine (L-
DOPA), and dihydroxyphenylacetic acid (DOPAC) content
of the tissue punch extracts was performed as described
previously [52]. Brieﬂy, the ﬁltered supernatants of each
tissue extract were injected directly via an HPLC pump
(Model 515, Waters, Milford, Mass, USA) onto a column
(Merck Chemicals, Ltd; c-18, 5µmp a r t i c l es i z e ,4 . 6m mi d
X 250mm, 30
◦C) coupled to an electrochemical detector
(Digital Electrochemical Amperometric Detector, Antec-
Leyden, Zeoterwoude, the Netherlands), and the oxidation
potential was set to 0.76V. The mobile phase (0.55g heptane
sulphonicacid,0.2gEDTA,16mLtriethylamine,12mL85%
phosphoric acid, and 40mL acetonitrile in 2L of water; pH
2.6)waspumpedat0.8mL/min.Monoamineandmetabolite
concentrations were expressed in relation to the protein
content of the samples, which were quantiﬁed with Bio-
Rad Protein Assay Kit. Results are presented in pmol/mg
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2.4. DHEA Determination. DHEA level was measured using
a DSL 9000 Active DHEA-coated tube radioimmunoassay
(RIA) kit (Diagnostic Systems Laboratories, Webster, Tex,
USA). 0.75mL limbic region homogenates were extracted
twice with 1mL diethylether, centrifuged at 350 g for 5
minutes and kept for about 15 minutes at −70
◦Ct oa l l o w
the aqueous phase to freeze. The etheric phase was decanted
into a new glass tube, evaporated till dryness and dissolved
in 120µL of standard 0 of the RIA kit. 100µLw e r eu s e df o r
the determination of DHEA [53]. The detection limit of the
assay is 0.07nmol/L; assay variability is 10.2% between runs
and 5.6–10.6% within runs according to the level of DHEA
in the sample; cross-reactivity with other steroids is <0.2%.
Results are presented in pmol/mg protein.
2.5. BDNF Determination. BDNF levels were determined
using BDNF Emax ImmunoAssay System (Promega Corpo-
ration, Madison, Wis, USA) as previously described [54].
2.6. Antidepressants Administration. At PND 21–23, anti-
depressant treatments were administered. Osmotic mini-
pumps (Alzet, Model 1002, 0.25µl per hour, 14 days) were
ﬁlled with the drugs (Fluoxetine, Desipramine, DHEAS—
all in concentrations of 8mg/kg initial BW/day) or saline,
and implanted subcutaneously in the rats from the 2 strains,
under anesthesia (Nembutal 30mg/kg). We preferred the
sulfate formation (DHEAS), because it dissolves with water,
whichallowstheuseofosmoticpumps,asopposedtoDHEA
that dissolves with oil.
The dose of the antidepressant treatments was chosen
according to several studies conducted on adult rats from
this strain [55–57]. Diﬀerent doses were used in these studies
ranging from 5–10mg/kg. We chose the dose of 8mg/kg
since this dose is in the middle of the range found eﬀective
in these studies and due to the fact that this study deals
with prepubertal rats that might show over-sensitivity to
the higher doses of the antidepressant treatments. After
two weeks in which the pumps slowly released the drugs
and the rats’ body weight increased dramatically, individual
doses ranged from 3.2–4.94mg/kg, with no signiﬁcant
between-group diﬀerences in dose. One way ANOVA on
the diﬀerent treatments at the diﬀerent ages (PND = 21 and
35) of the two strains (Wistar versus WKY) further showed
no signiﬁcant diﬀerences between the strains in pattern of
decrease in dose over time [F(7,35) = 0.69; NS]. At the age
of 34-35 days, the forced swim test procedure was conducted
(N in each group = 8).
2.7. Swim Test. The forced swim test developed by Porsolt
et al. [38] has become a widely used paradigm for studying
stress responses and screening antidepressant drugs ([39];
but see [40]). Prolonged immobility duration in this
test is sometimes regarded as behavioral despair, an animal
analogueofhumandepression.Thegeneralprocedureinthis
paradigm is to immerse rats or mice in a cylinder of water
from which there is no escape. Twenty-four hours later, rats
are retested for 5 minutes. Typically, animals paddle vigor-
ously when ﬁrst immersed, then become relatively immobile
and adopt a characteristic vertical ﬂoating response. When
observed during the retest period, they are more immobile
than during their initial immersion. In some variations of
the test, rats are only immersed once and immobility time
is recorded during this one-time only session [41, 42]. Abel
[39] has demonstrated that the vertical immobility response
in the forced swim test has a sudden onset, beginning
at 21 days of age and quickly stabilizing at 26 days of
age. Overstreet [43] and Yadid [44] have shown longer
immobility durations in adult Flinders Sensitive Line (FSL)
male rats compared to controls, using the modiﬁed “Porsolt”
paradigm—a one-session procedure. In addition, the predic-
tive validity of this modiﬁed paradigm has been supported
is several studies (e.g., [45, 46]). Using the same procedure,
in a reduced-size apparatus designed for prepubertal rats
[39], we similarly described longer immobility time in
prepubertal FSL and WKY rats, compared to their control
strains [11].
At the age of 34-35 days, after two weeks of anti-
depressant treatment, each male rat was weighed and then
immersed in a Plexiglas cylinder designed especially for
the size of prepubertal rats (height = 45.5cm, diameter
= 14.0cm) ﬁlled to 24cm with fresh tap water heated to
34 ± 1
◦C, for 5 minutes [39]. No animal was tested more
than once. Duration of ﬂoating/immobility behavior was
measured. The criterion for ﬂoating: making only the mini-
mal movements necessary to keep the head above water, with
no forelimb movements. The water was changed between
test animals. All tests were performed in a dark room and
during testing the Plexiglas cylinder was illuminated by two
25-Wred light bulbs, placed approximately 50 cm above
the cylinder. All tests were conducted between 10:00–13:00
hour.
2.8. Data Analysis. Quantiﬁcation of the 5-HT, 5-HIAA
content of the tissue punches extracts from each brain region
(Amygdala, VTA, NAc, and hypothalamus) was analyzed by
independent t-tests comparing the WKY and Wistar strains
(with a Bonferonni correction).
Quantiﬁcation of the HVA, DA, DOPA, DOPAC content
of the tissue punches extracts from each brain region
(Amygdala, VTA, NAc, and hypothalamus) were analyzed by
independent t-tests comparing the WKY and Wistar strains
(after a Bonferonni correction).
DHEA basal levels were analyzed by independent t-tests
comparing the WKY and Wistar strains, separately for each
brain region (Amygdala, VTA, NAc, and hypothalamus).
BDNF basal levels were analyzed by independent t-tests
comparing the WKY prepubertal rats and their Wistar
controls, separately for each brain region (CA3 & DG).
Immobility in the forced swim test and weight at PND
21 and 35 (the latter: the day in which the forced swim
test took place) of animals from the two strains (WKY and
Wistar) that received chronic administration of saline were
compared by t -tests for independent samples. This was in
order to compare the results from the current study with
former results from our lab, in which strain diﬀerences were
found [11].Advances in Pharmacological Sciences 5
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Figure 1: Mean basal levels of DHEA (± SEM) of 34-35 day old
Wistar and WKY rats. Levels in the VTA are divided by ten for
presentation purposes. ∗P<. 05.
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Figure 2: Mean basal levels of BDNF in the DG and CA3 (± SEM)
of 34-35 day old Wistar versus WKY rats (N = 5-6 each group).
∗P<. 05.
Inthesecondphase,antidepressanttreatmentdiﬀerences
were analyzed by two-way (strain X treatment) univari-
ate analyses of variance (ANOVA), followed by one way
ANOVAs, performed separately in each of the two strains,
with treatment (desipramine, ﬂuoxetine, DHEAS versus
saline) as the independent variable. In these ANOVAs,
immobility duration in the swim test, weight at PND
2 1a n dw e i g h ta tP N D3 5w e r et h ed e p e n d e n tv a r i a b l e s .
The ANOVAs were followed by Tukey’s HSD post-hoc
tests, examining the eﬀects of the diﬀerent antidepressant
treatments.
3. Results
The basallevels of monoamines in the diﬀerent brain regions
are presented in Table 1.A se v i d e n tf r o mTable 1,W K Y
prepubertalratsexhibitedsigniﬁcantlylowerlevelsof5HIAA
in the Nac (t(9) = 3.181; P<. 05) compared to their control
line. A non-signiﬁcant tendency was apparent also in HVA
levels (t(8) = 1.925; P<. 1). In the VTA, the WKY rats
exhibited higher levels of DOPA (t(5) = 4.84; P<. 01)
compared to their controls. WKY rats exhibited signiﬁcantly
higher levels of DOPAC (t(8) = 6.97; P<. 01) in the
hypothalamus, compared to their Wistar controls. Two other
apparent diﬀerences in this brain region, lower levels of
5HIAA(t(7) =2.399,P<. 05)andatendencytowardshigher
levels of DOPA (t(7) = 2.139; P<. 1) in WKY compared to
Wistar rats, did not reach statistical signiﬁcance, given the
Bonferonni correction. In the Amygdala, WKY rats showed a
nonsigniﬁcant tendency toward higher levels of 5HIAA (t(8)
= 2.355; P<. 05, Bonferonni correction = NS) compared to
Wistar controls.
The basal levels of DHEA in the diﬀerent brain regions
are presented in Figure 1. WKY rats exhibited signiﬁcantly
lower levels of DHEA in the VTA compared to their control
line-Wistar (t(5) = −2.605; P<. 05). No signiﬁcant diﬀer-
ences in DHEA levels were found in the other brain regions.
WKY prepubertal rats exhibited lower levels of BDNF in
the CA3 (t(7) = 2.73; P<. 05) compared to their Wistar
controls, while no signiﬁcant diﬀerences were found in the
DG (t(4) = 0.02; P = ns); (Figure 2).
As evident from Table 2, t-tests for independent samples
revealed that WKY rats weighed signiﬁcantly less (t(14) =
2.83; P<. 05) compared to Wistar controls (as was found
in a former study in our lab; [11]). T-tests for independent
samples also revealed that WKY rats at PND 35 exhibited
longer immobility duration in the forced swim test (t(14) =
3.34; P<. 05) compared to their Wistar controlled (Wistar
meanimmobilityduration(sec):115.625±3.466;WKYmean
immobility duration (sec): 244.37 ±17.28; P<. 05).
Analyzing the eﬀects of the antidepressant treatment on
swim-test immobility in the two strains by 2-way ANOVA
showed that WKY rats were signiﬁcantly more immobile
(mean = 174 sec) than Wistar rats (mean = 98), F(1,56)
= 17.06; P<. 001; and that treatment with DHEAS,
overall, signiﬁcantly reduced immobility duration compared
to saline treatment, F(3,56) = 2.84; P<. 05. Tukey’s post hoc
test (P<. 05) did not further show signiﬁcant diﬀerences
between the group that received saline and the groups that
received desipramine or ﬂuoxetine. The strain X treatment
interaction was not statistically signiﬁcant. One way ANOVA
on immobility levels of the Wistar rats in the swim test
revealed no signiﬁcant eﬀect for the treatment, F(3,28) =
0.41; P = N.S( Figure 3(a)). On the other hand, in the WKY
rats, treatment with DHEA signiﬁcantly reduced immobility
duration compared to saline treatment, F(2,28) = 3.76; P<
.05, Tukey’s post hoc test did not further show signiﬁcant
diﬀerences between the WKY rats that received saline and
those that received desipramine or ﬂuoxetine (Figure 3(b)).
Two-way ANOVAs on the rats’ body weights on PND21
and 35 showed that Wistar rats weighed signiﬁcantly more
than WKY rats, as expected (PND21 : F(1,35) = 24.17,
P<. 001; PND35 : F(1,35) = 59.80, P<. 001). However,
there were no signiﬁcant treatment diﬀerences or strain X
treatment interactions. In both the Wistar and the WKY rats,
at both ages, no signiﬁcant diﬀerences in body weight were
revealed between the treatment groups (PND21 : Wistar :
F(3,15) = 0.33; P = NS; WKY : F(3,12) = 1.5; P = N.S;
PND35 : Wistar : F(3,28) = 2.54; P = N.S; WKY: F(3,28) =
2.21; P = NS) (Table 2).6 Advances in Pharmacological Sciences
Table 1: Mean basal levels of monoamines and their metabolites in the four diﬀerent limbic brain regions (± SEM) of 34-35 day old Wistar
and WKY rats (pmol/mg protein).
Brain Region Strain DOPA DA DOPAC HVA 5HT 5HIAA
Nac Wistar 7.03 ±3.22 70.7 ±75 5 .6 ±8.23 0 .9 ±1.42 .95 ±0.21 1 .1 ±1.28
WKY 3.31 ±0.95 69.6 ±45 3 .6 ±2.62 6 ±1.5# 1.9 ±0.71 5.67 ±1.05∗
VTA Wistar 2 ±1.71 0 .9 ±5.11 6 .57 ±9.17 1.49 ± 0.68 3.48 ±2.32 4.58 ±2.96
WKY 14.15 ±1.7∗∗ 10.6 ±6.73 .12 ±1.35 .55 ±4.82 .48 ±1.21 .16 ±0.83
Hypothalamus Wistar 49.7 ±6.14 197 ±52.15 7 .6 ±2.93 0 .4 ±8.21 6 .56 ±4.4 114 ±10.2
WKY 88.2 ±17.2# 96 ±30.4 107.7 ±7.7∗∗ 31.8 ±9.51 7 .08 ±4.68 3 .8 ±5.7∗
Amydgala Wistar 11.84 ±1.67 6.88 ±1.22 .59 ±14 .70 ±1.12 .25 ±0.21 .38 ±0.8
WKY 8.35 ±1.27 .91 ±1.54 .74 ±1.22 .86 ±1.62 .02 ±1.14 .29 ±0.9∗
∗∗P<. 01 Wistar versus WKY; ∗P<. 05 Wistar versus WKY; #P<. 1W i s t a rv e r s u sW K Y .
Table 2: Weight in grams (mean ± SEM) of 21-day-old and 35-day-old Wistar and WKY rats in the diﬀerent treatment groups (DHEAS,
desipramine, ﬂuoxetine, saline).
Line Age Treatment Weight (gr.)
Wistar
PND 21
Saline 58.6 ±11.6
Fluoxetine 56.6 ±3.5
Desipramine 56.5 ±4.9
DHEAS 55.5 ±4.0
Saline1 106.2 ±6.6
PND 35
Fluoxetine 123.9 ±1.7
Desipramine 115.7 ±6.9
DHEAS 123.1 ±3.3
Saline 38.8 ±2.9
WKY
PND 21
Fluoxetine 33.6 ±2.6
Desipramine 29.6 ±1.2
DHEAS 34 ±3.8
Saline1 82.1 ±5.3
PND 35
Fluoxetine 72.5 ±4.7
Desipramine 71.0 ±3.0
DHEAS 67.9 ±2.7
1P<. 05 Wistar (saline) versus WKY (saline) at PND 35.
4. Discussion
In attempt to better understand the neurobiological basis
of childhood depression, we explored, in the main study,
monoamine and DHEA levels in the limbic system, and
BDNF levels in the hippocampus. Next, upon the results,
we performed a preliminary evaluation of a new and unique
potentialtreatmentapproachfordepressedchildren,namely,
DHEAS,usingprepubertalratsfromaputativeanimalmodel
of depression—the WKY strain and the Wistar strain as
their control (—as suggested by the results from several
studies conducted in our lab [10–12]). Finding eﬀective
antidepressant treatments in young WKY rats would also
provide support for their predictive validity as an animal
model for childhood/adolescent depression.
Because of their unique importance and inﬂuence on
depression, we focused on four subcortical areas in the
current research: NAc, VTA, amygdala, and hypothalamus.
Another important brain region which inﬂuences depression
and should be mentioned is the hippocampus; (for reviews
see [58, 59]). Following earlier ﬁndings [30] both in animal
and human studies, and the connections between BDNF and
serotonin in depression [34], we measured basal levels of
BDNF in two major brain regions in the hippocampus: DG
and CA3.
The results in the current study showed that WKY
prepubertal rats had lower basal levels of DHEA, compared
to their controls, in the VTA, a brain region suggested to be
central in reward and motivation [37]. Though not much
is known about the activity of the neurosteroid DHEA and
DHEAS in the brain, increasing data indicate an antidepres-
sant role for DHEA(S) (see [22] for review). In addition, a
positive relationship between DHEA and monoamines was
demonstrated; for example, DHEA administration caused a
signiﬁcant increase in serotonin levels in the PVN of the
hypothalamus [60]. The antidepressive eﬀect of DHEA mayAdvances in Pharmacological Sciences 7
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Figure 3: (a) Mean immobility duration in sec. (± SEM) of 35
days old Wistar rats after chronic administration of antidepressants
(desipramine, ﬂuoxetine, DHEAS) or saline (N = 8 in each group).
(b) Mean immobility duration in sec. (± SEM) of 35 days old WKY
rats after chronic administration of antidepressants (desipramine,
ﬂuoxetine, DHEAS) or saline (N = 8 in each group). ∗P<. 05.
be triggered by interaction with several diﬀerent receptors:
GABAA [61]; NMDA [62]; sigma-1 receptors [25, 63]. The
sigma-1receptorsweredemonstratedtoelicitnoradrenaline-
and serotonin-neurotransmission and considered to have a
role in the antidepressants eﬀect [64, 65]. Lower levels of
DHEA in regions of the WKY limbic system may explain
some of the depression-like symptoms detected in these
prepubertal rats, such as increased immobility time in the
forced swim test and abnormal social play [11].
The results from the monoamine measurements showed
that WKY prepubertal rats had lower levels of 5HIAA,
compared to their controls, in the Nac. Both animal [66]
and human (postmortem) studies [67] have revealed a close
correlation between brain and cerebrospinal ﬂuid (CSF)
5HIAA levels. Lowered CSF 5HIAA in depression was shown
to correlate positively with increased anxiety [68] as also
observed in the prepubertal WKY rats [10]. In addition,
WKY rats showed higher levels of DOPA in the VTA
and higher levels of dopamine metabolite (DOPAC) in the
hypothalamus in WKY compared to Wistar prepubertal
rats.
Taking together the ﬁndings of low levels of DHEA
in VTA of prepubertal WKY, together with the decreased
metabolism of serotonergic neurons in the hypothalamus
a n dN a c ,a sr e p o r t e di no t h e rs t u d i e s[ 60, 69] may indicate a
connection between these brain regions and neurochemical
mechanisms that contribute to “depression-like” symptoms
found in this strain. This connection may involve the
agonistic eﬀects of DHEA(S) on the activity of sigma 1
receptors [22, 26, 60, 69], as well as on the neural network
of these brain regions [70]. Future studies are needed to
determine the eﬀects of role neurochemical limbic network
in the “depressive-like” behaviors exhibited by this strain.
Alternatively, functional connection between the sero-
tonergic and dopaminergic system in the limbic circuit
was suggested to play a role in depressive behavior [44].
Alterations in DHEA and limbic dopamine turnover were
demonstrated recently [33], and serotonin receptors have
been found activating a large population of dopaminergic
neurons in the VTA [71]. Hence, DHEA may change sero-
tonergic tone, which may lead to alteration in dopaminergic
functioning as implied in depression [72]. The higher levels
of DOPAC in the hypothalamus exhibited by the WKY
prepubertal rats in this study may thus be explained by the
abnormal levels of serotonin in these structures, as a result of
abnormal DHEA levels in the VTA of theses animals.
From the BDNF results it seems that prepubertal WKY
rats exhibit lower levels of BDNF in the hippocampus (at
least in one region-CA3) as has been found in several human
studies [73] and animal studies [30], and in accordance with
the BDNF theory of depression.
Recently, a study measuring BDNF and TrkB levels in the
hippocampus of prepubertal rats following antidepressants
treatment showed increased BDNF protein and mRNA, as
well as TrkB mRNA, at diﬀerent ages (PND 13, 21, 28) [74].
The results from this study, together with the results from
our study using an animal model of childhood depression
[11], might indicate that BDNF has a key role in childhood
depression.
However, it is noteworthy to mention, that the evidence
for the involvement of BDNF in the pathophysiology of
depression is currently inconsistent. On one hand, as
described above, decreased BDNF levels are associated with
both human depression and “depressive-like behavior” in
rodent models of the disorder. A number of clinically
eﬀective antidepressants increase BDNF levels, while direct
BDNF infusions and genetic overexpression demonstrate
antidepressant-like activity. On the other hand, a number
of pharmacological studies have generated negative results,
while others describe ﬁndings directly contradicting a simple
casual relationship between total brain BDNF levels and
mood (see [30] for review).8 Advances in Pharmacological Sciences
In the second phase of the current study, we chronically
administrated two diﬀerent antidepressant treatments (ﬂu-
oxetine and desipramine), DHEAS and saline to prepubertal
rats from the two strains. Though prepubertal WKY rats
treated by desipramine or ﬂuoxetine appeared to exhibit
lower immobility duration in the forced swim test, only
treatment with DHEAS produced a signiﬁcant decrease in
immobility, compared to saline-administered controls. Wis-
t a rc o n t r o l sw e r en o ta ﬀected by any of the antidepressants.
TheseresultsareinaccordancewiththelowerlevelsofDHEA
found in the VTA of the WKY rats in ﬁrst phase of our study
(This study, though, should be regarded as a preliminary
examination, as a dose-response, multimeasure experiment
with a greater number of subjects is clearly needed to clarify
the relative potency of the diﬀerent treatments). However,
though DHEAS may be synthesized in the brain from
DHEA, they are not the same hormones and they may act
through diﬀerent mechanisms [22]. Therefore one of the
limitations of the current study is the use of DHEAS (and
not DHEA) as a neurosteroid antidepressant treatment (due
to the limitations of the osmotic minipumps) in the second
phase of the study.
Chronic administration of tricyclics, such as desipra-
mine, improves most of the “depressive-like” symptoms
e x h i b i t e db yW K Ya d u l tr a t s[ 55, 75]. Other studies showed
that selective 5HT reuptake inhibitors such as ﬂuoxetine,
onlyaﬀectaportionoftheserotonin-receptorbindingcapac-
ity in the brain [56, 57]. The diﬀerences between the results
in the current study and ﬁndings from other studies [75]
might explain the weak response of depressed prepubertal
children to conventional, clinically used antidepressants, in
contrast to adults [6], emphasizing the pharmacological dif-
ferencesbetweenadultdepressionandchildhooddepression,
and the need for speciﬁc and novel therapeutic strategies for
childhood depression.
In addition, the current results indicate that young WKY
rats receiving 14 d saline administration exhibited longer
immobility duration in the forced swim test and weighed
signiﬁcantlylesscomparedtoWistarcontrols,asinuntreated
na¨ ıve prepubertal rats [11]. We did not ﬁnd treatment X
group eﬀects on body weight, at the onset (PND 21) and
end (PND 35) of the study, in both Wistar and WKY rats.
Although the dose selected was adjusted to the weight of the
rat at the beginning of the study, this dose gradually changed
during the experiment since the subjects’ weights changed.
However, analyzing the dose at the end of the study and the
rate of change between the treated groups showed no signif-
icant between-group diﬀerences. Importantly, even though
there was a gradual decrease in the dose over ontogeny, a
signiﬁcant eﬀect on swim-test immobility was found.
High ratio of corticosterone/DHEA may be associated
with depression (e.g., [76]). In previous studies in our
laboratory, thirty-ﬁve-day-old WKY rats have displayed high
levels of plasma corticosterone (CORT) and adrenocorti-
cotropic hormone (ACTH) [11]. Hence, chronic adminis-
tration of DHEAS in our study might have decreased the
ratio of CORT/DHEA, consequently alleviating depression-
like symptoms exhibited by the WKY prepubertal rats. How-
ever, one should consider that a disassociation might exist
between DHEAS and ACTH, for example, during (chronic)
stress or medical illness [77], and the fact that DHEA levels
can be regulated independently of cortisol/corticosterone
[78]. Thus, the DHEAS eﬀect seen in this study may be
explained by other neuromechanisms, such as enhancement
of norepinephrine [79] and serotonin [80].
A recent study showed that DHEA can render an
otherwise ineﬀective dose of ﬂuoxetine capable to increase
progenitor cell proliferation to the same extent as doses
four times higher [81]. However, this synergistic action did
not appear to be mediated by alterations in BDNF gene
expression, or by TrkB, mineralcorticoid, glucocorticoid,o
or 5HT1A receptor expression in the DG, or by altered
levels of plasma corticosterone. We note that this study was
conducted in brain samples, no behavioral paradigms were
employed, and the samples were from wild-type rats—not
“animal models of depression.”
Former results suggesting an antidepressant-like eﬀect
of DHEA in adult rats of a diﬀerent strain exhibiting
“depression-like” symptoms [53] and humans [23] together
with our current data suggest that the neurosteroids
DHEA(S) may be a promising adjunct treatment approach
for depressed adults and especially for depressed children
and adolescents (while closely monitoring sexual maturation
and HPA axis activity) who fail to respond to the available
monoaminergic antidepressant treatments. According to our
resultsshowingabnormalbasallevelsofBDNF,togetherwith
the ﬁndings showing the interactions between serotonin,
BDNF, and DHEA [34], it seems that BDNF might be a
possible mediator of the DHEA antidepressive activity (the
results of [81] notwithstanding). However, further studies
needtobeconductedinthefuturetodeterminethispotential
pathway.
Please note that this paper does not attempt to suggest
wide use of DHEA nor DHEAS as antidepressants for
childhood depression but it only explores the possibility that
DHEA(S), at low doses and/or in conjunction with clinically
used antidepressants may have therapeutic potential in some
cases. The use of this neurosteroid in depressed children
and adolescents should be further evaluated and closely
monitored in order to prevent unwarranted side eﬀects. In
addition, it is noteworthy to mention four major limitations
of the current study: (1) there are diﬀerences between
rodents and humans in brain DHEA expression—in rodents
brainDHEAisderivedmainlyifnotsolelyfromlocalsynthe-
sisandnotfromperipheralsynthesis,whileinhumanbeings,
brain DHEA may be derived from both local synthesis and
peripheral synthesis [22]. (2) DHEA and DHEAS concentra-
tions typicallydecreasesteadilywith age[22].Thoughearlier
studies showed developmental diﬀerences between WKY
and Wistar controls [12] indicating abnormal diﬀerences
related to childhood depression, in the current study there
were no direct comparisons between the prepubertal rats
to older age groups, making it diﬃcult to establish whether
the observed eﬀects are related to childhood depression per
se or represent general diﬀerences between the WKY strain
and their corresponding controls. (3) There are diﬀerences
between rats and humans in the developmental course
of DHEA and DHEAS—prepubertally, humans undergoAdvances in Pharmacological Sciences 9
adrenarche, the maturation of the adrenal gland, and after
that the entire system is much diﬀerent than in a truly
juvenile state. Rats do not go through adrenarche, so the
applicability of the rat as an animal model of DHEA-
depression-development is questionable. (4) In an attempt
to avoid the inﬂuence of gender and female sex hormones
on developmental characteristics, only males were examined
in the current study, therefore further studies need to be
conducted in order to explore the involvement of DHEA(S)
in childhood depression in females.
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